Pharming Group N.V. (PHAR) DCF Valuation

Pharming Group N.V. (PHAR) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Pharming Group N.V. (PHAR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to evaluate the intrinsic value of Pharming Group N.V.? Our (PHAR) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your projections and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 197.4 238.1 197.9 214.4 255.7 275.8 297.4 320.7 345.9 373.0
Revenue Growth, % 0 20.63 -16.88 8.31 19.3 7.84 7.84 7.84 7.84 7.84
EBITDA 74.5 96.0 50.9 35.0 10.3 68.5 73.8 79.6 85.9 92.6
EBITDA, % 37.74 40.33 25.69 16.31 4.03 24.82 24.82 24.82 24.82 24.82
Depreciation 6.0 8.7 20.4 13.7 16.6 16.5 17.8 19.2 20.7 22.3
Depreciation, % 3.06 3.64 10.33 6.41 6.49 5.99 5.99 5.99 5.99 5.99
EBIT 68.4 87.4 30.4 21.2 -6.3 51.9 56.0 60.4 65.1 70.2
EBIT, % 34.68 36.69 15.36 9.89 -2.47 18.83 18.83 18.83 18.83 18.83
Total Cash 77.4 214.2 199.9 216.2 222.5 229.6 247.6 267.0 287.9 310.5
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 27.4 20.1 16.6 20.4 44.4
Account Receivables, % 13.88 8.43 8.37 9.52 17.37
Inventories 16.9 22.1 28.4 44.1 59.2 41.9 45.2 48.7 52.5 56.6
Inventories, % 8.56 9.28 14.37 20.58 23.14 15.19 15.19 15.19 15.19 15.19
Accounts Payable 37.8 14.0 5.4 6.3 15.1 20.2 21.8 23.5 25.3 27.3
Accounts Payable, % 19.13 5.9 2.71 2.95 5.92 7.32 7.32 7.32 7.32 7.32
Capital Expenditure -26.5 -17.2 -16.6 -2.1 -1.5 -16.9 -18.2 -19.6 -21.2 -22.8
Capital Expenditure, % -13.44 -7.21 -8.41 -0.96147 -0.59678 -6.12 -6.12 -6.12 -6.12 -6.12
Tax Rate, % 12.19 12.19 12.19 12.19 12.19 12.19 12.19 12.19 12.19 12.19
EBITAT 53.1 69.5 22.1 19.4 -5.5 42.5 45.8 49.4 53.2 57.4
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 26.1 39.4 14.4 12.5 -20.7 77.1 41.2 44.4 47.9 51.7
WACC, % 8.15 8.15 8.15 8.17 8.16 8.16 8.16 8.16 8.16 8.16
PV UFCF
SUM PV UFCF 211.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 53
Terminal Value 856
Present Terminal Value 578
Enterprise Value 790
Net Debt 114
Equity Value 675
Diluted Shares Outstanding, MM 657
Equity Value Per Share 1.03

What You Will Get

  • Real Pharming Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Pharming Group N.V. (PHAR)’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Pharming Group N.V. (PHAR).
  • WACC Calculator: Includes a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the pharmaceutical industry.
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Pharming Group N.V. (PHAR) projections.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Pharming Group N.V. (PHAR).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  • Step 1: Download the prebuilt Excel template with Pharming Group N.V. (PHAR) data included.
  • Step 2: Explore the pre-filled sheets and understand the key metrics related to Pharming Group N.V. (PHAR).
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins) specific to Pharming Group N.V. (PHAR).
  • Step 4: Instantly view recalculated results, including Pharming Group N.V. (PHAR)'s intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs for Pharming Group N.V. (PHAR).

Why Choose This Calculator for Pharming Group N.V. (PHAR)?

  • Accurate Data: Up-to-date Pharming financials provide dependable valuation outcomes.
  • Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Built-in calculations save you from starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Clear layout and step-by-step guidance make it accessible for all users.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for portfolio evaluation in Pharming Group N.V. (PHAR).
  • Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Pharming Group N.V. (PHAR).
  • Students and Educators: Leverage real-world data to enhance learning and practice in financial modeling.
  • Healthcare Analysts: Gain insights into how biotech companies like Pharming Group N.V. (PHAR) are valued in the market.

What the Template Contains

  • Pre-Filled Data: Includes Pharming Group N.V.'s historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Pharming Group N.V.'s profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

Es wurden keine passenden Produkte gefunden.